Category : Clinical Research, Pharma & Healthcare Financing

Funding expands research to redesign the science of women’s wellness SheMed, the female-founded health technology company changing how women access personalised healthcare, today announced it...

Data presented at the CHEST 2025 Annual Meeting highlight deupirfenidone’s differentiated profile and potential to address unmet needs across age groups PureTech Health plc (Nasdaq:...

Results from a US multicenter study presented at CHEST show e-Lung could have sped up Progressive Pulmonary Fibrosis (PPF) diagnosis by up to 21 months...

Founder Jeff Molloy urges reform as insurance leaders gather at HLTH 2025: “ShopADoc.com doesn’t replace insurance—it redefines how dental affordability works.” As HLTH 2025 opens in...

With backing from Peter Thiel, K5 Global, Jeff Bezos, and Wellington Management, among others, HistoSonics is positioned to expand globally across new clinical applications HistoSonics,...

HARMONi-GI3 is the Fourth Global Phase III Study of Ivonescimab and First Global Study beyond NSCLC Clinical Trial Site Activations Planned to Begin This Quarter...

With more than 2,000 citations and year-over-year growth nearing 80%, TriNetX outpaces competitors and fuels high-impact science published in top medical journals.  TriNetX, driven by...

California based Graph AI, focused on patient safety and pharmacovigilance, announced its $3 million Seed round, led by Bessemer Venture Partners. The investment will enable...

Lubrizol announces new preclinical findings confirming the superior performance of its microencapsulated iron ingredient, Lipofer™ microcapsules, compared to conventional iron sources. The study, published in Nature,...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces completion of Phase 1a clinical trial with TTX-MC138, an investigational inhibitor of microRNA-10b, or miR-10b. By meeting its primary safety...

Trinity Capital Inc. (Nasdaq: TRIN) (the “Company”), a leading alternative asset manager, today announced the commitment of $130 million in growth capital to Candel Therapeutics, Inc. (Nasdaq: CADL) (“Candel”), a...

SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868), a global Ph2/3 registrational study of...

New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development.  Alamar Biosciences, a company powering precision proteomics to enable...

Berlin Heals Holding AG, a leading clinical-stage medical device company focused on revolutionizing the care of Heart Failure with a first of its kind durable...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the Phase 3 ORBIT-EXPANSE...